Documentos relacionados

1. Comparison of efficacy and safety of daily oral L-arginine and PDE5Is alone or combination in treating erectile dysfunction: A systematic review and meta-analysis of randomised controlled trials.
2. Pharmacokinetics, mass balance, and metabolism of [¹⁴C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension.
3. Computational design, synthesis and biological evaluation of PDE5 inhibitors based on N²,N⁴-diaminoquinazoline and N²,N⁶-diaminopurine scaffolds.
4. Efficacy and safety of PDE5 inhibitors in middle-aged and old patients with and without hypogonadism.
5. The effect of combination treatment with low-intensity shockwave therapy and daily tadalafil on severe erectile dysfunction: a double-blind, randomized, sham-controlled clinical trial.
6. Re: Placebo Responses among Men with Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-Analysis.
7. Intracavernosal OnabotulinumtoxinA Exerts a Synergistic Pro-Erectile Effect When Combined With Sildenafil in Spontaneously Hypertensive Rats.
8. A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Therapeutic Confirmatory Study to Evaluate the Safety and Efficacy of Avanafil in Korean Patients with Erectile Dysfunction.
9. Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health.
10. [Pulmonary arterial hypertension (PAH ) : a new era of pulmonary arterial vasodilatators].